Boudewijn van Vliet
Director/Board Member bei PRYME N.V.
Profil
Boudewijn van Vliet currently works at Antion Biosciences SA, as Director from 2023 and Pryme NV, as Member-Supervisory Board from 2022.
Aktive Positionen von Boudewijn van Vliet
Unternehmen | Position | Beginn |
---|---|---|
PRYME N.V. | Director/Board Member | 11.02.2021 |
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | Director/Board Member | 09.08.2023 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
PRYME N.V. | Industrial Services |
Private Unternehmen | 1 |
---|---|
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | Health Technology |